Experience with the treatment of cryptococcal meningitis

Česká verzia

Authors: J. Chmelař ^1,2; L.siráková ²; P. Šmahel ^1,2; Š. Rumlarová ^1,2; S. Plíšek ¹; R. Chlíbek ²; J. Smetana ²
Authors place of work: Klinika infekčních nemocí LF UK a FN Hradec Králové ¹; Katedra epidemiologie, Hradec Králové, Fakulta vojenského zdravotnictví Univerzity obrany v Brně ²
Published in the journal: Cesk Slov Neurol N 2022; 85(2): 189-190
Category: Letters to Editor
doi: https://doi.org/10.48095/cccsnn2022189

Zdroje

1. Beneš J (ed). Kryptokokóza. In: Infekční lékařství. Praha: Galén 2009: 315.

2. Iyer KR, Revie NM, Fu C et al. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. Nat Rev Microbiol 2021; 8: 1–13. doi: 10.1038/ s41579-021-00511-0.

3. Guess TE,Rosen J, Lopez NC et al. An inherent T cell deficit in healthy males to C. neoformans infection may begin to explain the sex incidenceof cryptococcosis. Biol Sex Differ 2019; 10: 44. doi: 10.1186/ s13293-019-0258-2.

4. Rajasingham R, Smith RM, Park BJ et al. Global burden of disease of HIV-associated cryptococcal meningitis: an update analysis. Lancet Infect Dis 2017; 17(8): 873–881. doi: 10.1016/ S1473-3099(17)30243-8.

5. Rozsypal H, Systémová antimykotika. Klin Farmakol Farm 2008; 22(1): 40–44.

6. Perfect JR, Dismukes WE, Dromer F et al. Clinical Practices guidelinesfor the managementof cryptoccocal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50(3): 291–322. doi: 10.1086/ 649858.